FDA sets July 29, 2026 PDUFA date for Outlook Therapeutics (OTLK) ONS-5010 BLA
Rhea-AI Filing Summary
Outlook Therapeutics reported that the U.S. FDA has acknowledged receipt of its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for wet age-related macular degeneration. The FDA classified the resubmission as a Class 1 review, triggering a 60-day review period and setting a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2026.
The company describes ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab that is already covered by centralized Marketing Authorization in the EU and authorization by the UK MHRA for wet AMD, with commercial launch commenced in Germany, Austria, and the UK. In the United States, the product remains investigational and subject to the outcome of this BLA review.
Positive
- FDA acceptance and Class 1 review of resubmitted BLA: The FDA has acknowledged receipt of Outlook Therapeutics’ resubmitted BLA for ONS-5010/LYTENAVA for wet AMD and designated it as a Class 1 review with a 60-day timeline and PDUFA target action date of July 29, 2026.
- Established European and UK regulatory footing: The company reports that LYTENAVA (bevacizumab gamma) holds Marketing Authorization from the European Commission and UK MHRA for wet AMD, with commercial launch commenced in Germany, Austria, and the UK, indicating existing non-U.S. market presence for its lead product.
Negative
- None.
Insights
FDA acceptance of the resubmitted BLA sets a clear, near-term U.S. regulatory decision date for Outlook Therapeutics’ lead asset.
The company states that the FDA has accepted the resubmitted BLA for ONS-5010/LYTENAVA for wet AMD as a Class 1 review, creating a 60-day review window with a PDUFA target action date of July 29, 2026. This step confirms that the agency considers the filing complete for review.
ONS-5010/LYTENAVA is already described as having Marketing Authorization in the EU and UK, with commercial launch started in Germany, Austria, and the UK. The U.S. BLA outcome will be important for aligning U.S. status with existing European authorizations.
The company highlights extensive forward-looking statements and risk factors, including regulatory uncertainties and broader macroeconomic risks referenced in its September 30, 2025 Form 10-K and subsequent filings. The actual impact for investors will depend on the FDA’s decision by the stated PDUFA date.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
|
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
(
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
On June 16, 2026, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration (the “FDA”) had acknowledged receipt of its resubmission of the Biologics License Application (the “BLA”) for ONS-5010 (bevacizumab-vikg). The FDA determined that the BLA is a Class 1 review, which results in a 60-day review period from the date of resubmission. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release, dated June 16, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Outlook Therapeutics, Inc. | ||
| Date: June 16, 2026 | By: | /s/ Lawrence A. Kenyon |
| Lawrence A. Kenyon | ||
| Chief Financial Officer | ||
Exhibit 99.1
Outlook Therapeutics
Announces FDA Acceptance of Resubmitted Biologics
License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a
Treatment
for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026
ISELIN, N.J., June 16, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.
“We are very pleased that the FDA has accepted our resubmitted BLA to review the labelling as part of the final step toward potential approval,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “This is great news for Outlook and the LYTENAVA™ team, patients and the retina community. We look forward to collaborating with the FDA over the coming weeks. We are incredibly grateful to our teams, partners, and KOLs for their resilience and dedication.”
When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance. Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, ONS-5010/LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.
In the United States, ONS-5010/LYTENAVA ™ (bevacizumab-vikg) is investigational. When approved, it will be the first ophthalmic formulation approved by the FDA.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™
(bevacizumab-vikg, bevacizumab gamma). LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European
Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch
of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”.
All statements other than statements of historical facts are “forward-looking statements,” including those relating to future
events. In some cases, you can identify forward-looking statements by terminology such as “can,” “potential,”
“target,” when, or “would”, the negative of terms like these or other comparable terminology, and other words
or terms of similar meaning. These include, among others, plans for continued engagement with the FDA and the potential to agree on a
regulatory pathway for ONS-5010, the potential of ONS-5010/LYTENAVA™ as a treatment for wet AMD, the potential for ONS-5010 to receive
approval from the FDA, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable
basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook
Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are
difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing
pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory
bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC),
including its Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as
updated by the Outlook Therapeutics’ subsequent filings,
which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of global
geopolitical conflict, tariffs and trade tensions, fluctuations in interest rates and inflation, and
potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those
expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release
are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update,
amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may
be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com